Novartis is pioneering the way in the class of cell and gene treatment and has developed the first CAR-T cell therapy approved for paediatric and young adult patients with relapsed/refractory B …

By sharing personal perspectives, we hope to empower patients and caregivers to learn more about CAR-T cell therapy and shed light on some of the most important, but sometimes less known, aspects of the lymphoma treatment journey. CAR-T Revelations: Insights from people that have received CAR-T cell therapy Together with the Leukemia and Lymphoma Society (LLS), we are unveiling revelations ...

Dec 13, 2021 · T-Charge is a next-generation CAR-T platform, innovated at the Novartis Institutes for BioMedical Research (NIBR), that will serve as the foundation for various new investigational CAR-T cell therapies in the Novartis pipeline.

Aug 30, 2017 · Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah (TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice

Novartis has a deep CAR-T pipeline. Our focus is to broaden the impact of cell therapy in oncology by going deeper in B-cell malignancies, potentially reaching patients in other hematological cancers and solid tumors and researching potential next-generation CAR-Ts that focus on new targets and utilize new technologies.

Novartis is the first to develop CAR-T cell therapy in collaboration with an academic institution. Novartis partnered with the University of Pennsylvania to pioneer the commercial CAR-T cell therapy manufacturing process.

Novartis Pharma AG; 2018. Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.

Novartis has created a sophisticated process for manufacturing CAR T Cell Therapies. Novartis CAR-T Cell theapy is developed using the patient's own T-Cells which are part of the body immune system and play a central role in fighting disease.

Oct 13, 2017 · Through a collaboration with the University of Pennsylvania (Penn), Novartis made an early commitment to the emerging field of CAR-T therapies. Its facility in Morris Plains, New Jersey, was the first manufacturing site approved by the US Food and Drug Administration (FDA) for immunocellular therapy production in the US, and has manufactured ...

Discover the Novartis pipeline of over 100 projects in clinical development, many for medicines that could advance treatment standards for patients.